Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version
- PMID: 30993900
- PMCID: PMC6593657
- DOI: 10.1111/cob.12310
Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version
Abstract
The Impact of Weight on Quality of Life-Lite (IWQOL-Lite) is widely used in evaluations of weight-loss interventions, including pharmaceutical trials. Because this measure was developed using input from individuals undergoing intensive residential treatment, the IWQOL-Lite may include concepts not relevant to clinical trial populations and may be missing concepts that are relevant to these populations. An alternative version, the IWQOL-Lite Clinical Trials Version (IWQOL-Lite-CT), was developed and validated according to the US Food and Drug Administration's (FDA's) guidance on patient-reported outcomes. Psychometric analyses were conducted to validate the IWQOL-Lite-CT using data from two randomized trials (NCT02453711 and NCT02906930) that included individuals with overweight/obesity, with and without type 2 diabetes. Additional measures included the SF-36, global items, weight and body mass index. The IWQOL-Lite-CT is a 20-item measure with two primary domains (Physical [seven items] and Psychosocial [13 items]). A five-item Physical Function composite and Total score were also supported. Cronbach's alpha and intraclass correlation coefficients exceeded 0.77 at each time point; patterns of construct validity correlations were consistent with hypotheses; and scores demonstrated treatment benefit. The IWQOL-Lite-CT is appropriate for assessing weight-related physical and psychosocial functioning in populations commonly targeted for obesity clinical trials. Qualification from the FDA is being sought for use of the IWQOL-Lite-CT in clinical trials to support product approval and labelling claims.
Keywords: Impact of Weight on Quality of Life-Lite (IWQOL-Lite); Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT); health-related quality of life; patient functioning; psychometric validation.
© 2019 Novo Nordisk A/S. Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Conflict of interest statement
This study was conducted under a research contract between Novo Nordisk and RTI Health Solutions and was funded by Novo Nordisk. R.L.K. is a consultant for Novo Nordisk and RTI Health Solutions. V.S.L.W., C.M.E., N.W., S.Q. and S.E.F. are salaried employees of RTI Health Solutions. H.H.M. and L.H.S. are salaried employees of Novo Nordisk.
Figures
References
-
- Ul‐Haq Z, Mackay DF, Fenwick E, Pell JP. Meta‐analysis of the association between body mass index and health‐related quality of life among adults, assessed by the SF‐36. Obesity (Silver Spring). 2013;21:E322‐E327. - PubMed
-
- Andresen EM, Meyers AR. Health‐related quality of life outcomes measures. Arch Phys Med Rehabil. 2000;81 (12 Suppl 2):S30‐S45. - PubMed
-
- Warkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of weight loss on health‐related quality of life: systematic review and meta‐analysis of randomized trials. Obes Rev. 2013;15:169‐182. - PubMed
-
- Optum Inc . SF health surveys. http://campaign.optum.com/optum-outcomes/what-we-do/health-surveys/sf-36.... Accessed October 10, 2018.
-
- Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Med Care. 1981;19:787‐805. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
